Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

View Cancer Clinical Trials

BMTCTN 1205   |   14-326
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia and A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies

Blood & Marrow Transplant (BMT)
Hematologic Malignancy
Main Campus
Phase 3

Contact Information
Cancer Answer Line


8:00 am - 4:30 pm, Monday - Friday

Primary Objective

To compare objective comprehension scores on the Quality of Informed Consent (part A) instrument between patients randomized to the ETRIC versus the standard consent arms.

Secondary Objectives

To compare the following measures between the two arms: (1) subjective comprehension scores on the Quality of Informed Consent (part B) instrument and the modified Deaconess Informed Consent Comprehension Test instrument, (2) state anxiety scores on State Trait Anxiety Inventory instrument, (3) satisfaction scores, (4) time taken for information location, and (5) patient consent rates on parent clinical trials.

Inclusion Criteria
Inclusion and exclusion criteria for the ETRIC study will be the same as the eligibility criteria for the BMT CTN 1101 and 1203 studies. Additional inclusion criterion specific for the ETRIC study will include:
  1. Adult patients (≥ 18 years)
  2. Speaking and reading proficiency in English
  3. Willing and able to provide informed consent for the ETRIC study
  4. Stated willingness to comply with study procedures and reporting requirements

Exclusion Criteria
Exclusion Criteria Not Available

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.